CA2260892A1 - Coupe-faim - Google Patents

Coupe-faim Download PDF

Info

Publication number
CA2260892A1
CA2260892A1 CA002260892A CA2260892A CA2260892A1 CA 2260892 A1 CA2260892 A1 CA 2260892A1 CA 002260892 A CA002260892 A CA 002260892A CA 2260892 A CA2260892 A CA 2260892A CA 2260892 A1 CA2260892 A1 CA 2260892A1
Authority
CA
Canada
Prior art keywords
tryptophan
neurotransmitter
amount
dose
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002260892A
Other languages
English (en)
Inventor
Mark E. Jarmel
William E. Shell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NUTRACORP SCIENTIFIC Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2260892A1 publication Critical patent/CA2260892A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Confectionery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un procédé et une composition permettant de diminuer l'appétit et l'envie de glucides à l'aide de précurseurs des neurotransmetteurs sérotonine, dopamine, noradrénaline et histamine, parmi lesquels les précurseurs tryptophane, phénylalanine, tyrosine et histidine. Les précurseurs sont combinés entre eux et avec des xanthines afin de produire un effet synergique qui permet de réduire avantageusement les doses de précurseurs. L'administration simultanée d'histidine et de tryptophane, de phénylalanine ou de tyrosine a un effet de potentialisation sur la suppression de l'appétit. Les xanthines, comprenant la théobromine, la caféine et le cacao, agissent comme agents de potentialisation des précurseurs, individuellement et dans des combinaisons de précurseurs. On utilise des formulations séparées de tyrosine et/ou phénylalanine avec des xanthines en même temps qu'une formulation de tryptophane avec des xanthines, chacune étant administrée séparément à des intervalles d'au moins 20 minutes. Dans ces combinaisons, on utilise une protéine hydrolysée comme source naturelle de tryptophane, ainsi qu'un glucide produisant de l'insuline afin d'éliminer de la circulation sanguine les acides aminés qui pourraient sinon entrer en compétition avec le tryptophane pour traverser la barrière hémato-encéphalique. Selon une variante, une protéine non hydrolysée peut être administrée en même temps qu'une enzyme protéolytique afin de produire du tryptophane dans le tube digestif.
CA002260892A 1996-07-17 1997-07-16 Coupe-faim Abandoned CA2260892A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68353596A 1996-07-17 1996-07-17
US08/683,535 1996-07-17
PCT/US1997/012408 WO1998002165A1 (fr) 1996-07-17 1997-07-16 Coupe-faim

Publications (1)

Publication Number Publication Date
CA2260892A1 true CA2260892A1 (fr) 1998-01-22

Family

ID=24744444

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002260892A Abandoned CA2260892A1 (fr) 1996-07-17 1997-07-16 Coupe-faim

Country Status (7)

Country Link
EP (1) EP0912181A1 (fr)
JP (1) JP2000515139A (fr)
KR (1) KR20000023819A (fr)
AU (1) AU3666497A (fr)
CA (1) CA2260892A1 (fr)
IL (1) IL127684A0 (fr)
WO (1) WO1998002165A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000184A2 (fr) * 1998-06-26 2000-01-06 Delack Elaine A Traitement de la sclerose en plaques
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
US6610277B2 (en) * 2000-12-27 2003-08-26 Arthur Zuckerman Appetite suppressant toothpaste
US6485710B2 (en) * 2000-12-27 2002-11-26 Arthur Zuckerman Appetite suppressant toothpaste
US7048941B2 (en) 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
JP2005538704A (ja) 2002-07-01 2005-12-22 ユニリーバー・ナームローゼ・ベンノートシヤープ 満腹誘導組成物
US7585523B2 (en) * 2002-08-27 2009-09-08 Targeted Medical Pharma Composition and method to augment and sustain neurotransmitter production
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
EP1534314B1 (fr) * 2002-09-04 2014-10-22 DSM IP Assets B.V. Composition nutritionnelle et thérapeutique d'un agent sensibilisant à l'insuline et d'une fraction peptidique
WO2004023647A1 (fr) 2002-09-06 2004-03-18 Telefonaktiebolaget Lm Ericsson Amplificateur de puissance composite
US7115285B2 (en) * 2003-03-14 2006-10-03 Eurark, Llc Composition and method for appetite and craving suppression and mood enhancement
KR20070034528A (ko) * 2004-05-27 2007-03-28 캄피나 네덜란드 홀딩 베.붸. Ｄｐｐ－ｉｖ 매개 질병의 예방 및／또는 치료용 의약품제조를 위한 단백질 가수분해물의 용도
WO2006053217A1 (fr) * 2004-11-12 2006-05-18 Mccleary, Edward Larry Composition et procede de perte de poids
JP5068174B2 (ja) 2004-12-23 2012-11-07 カンピナ ネーデルランド ホールディング ビー．ブイ． Ｄｐｐ−ｉｖを阻害するペプチド中に濃縮されたタンパク質の加水分解物及びその使用
GB0520917D0 (en) * 2005-10-14 2005-11-23 Zumbe Albert Chocolate based appetite suppressant
EP1954299B1 (fr) 2005-11-30 2016-01-13 Campina Nederland Holding B.V. Utilisation d'un hydrolysat de protéines pour augmenter l'activité du glp-1
JP2008094787A (ja) * 2006-10-13 2008-04-24 Paq Kk 落花生処理物を用いた交感神経興奮剤
GB0719542D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Use of cocoa extract
GB0719545D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Novel use of cocoa extract
GB0719544D0 (en) 2007-10-08 2007-11-14 Barry Callebaut Ag Cocoa extract and use thereof
ES2325435B1 (es) 2008-01-02 2010-06-17 Armando Jose Yañez Soler Composicion a base de cacao y espirulina.
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
JP4691571B2 (ja) 2008-03-04 2011-06-01 株式会社マルハニチロ食品 摂食調節剤
JP4593639B2 (ja) 2008-03-04 2010-12-08 株式会社マルハニチロ食品 ペプチド含有摂食調節剤
US11806352B2 (en) 2010-05-19 2023-11-07 Upfield Europe B.V. Theobromine for increasing HDL-cholesterol
JP6041242B2 (ja) * 2010-10-05 2016-12-07 ディーエスエム アイピー アセッツ ビー．ブイ． トリプトファンを含有するペプチド
JP5886657B2 (ja) * 2012-02-29 2016-03-16 株式会社ファンケル 小麦フスマ由来の粉末を含有する製剤
US20140129484A1 (en) * 2012-11-02 2014-05-08 Dsm Ip Assets B.V. Method of marketing protein hydrolysate for high energy sensation
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3867539A (en) * 1973-04-27 1975-02-18 Us Health Method of producing anorexia as a treatment for obesity
FI772858A (fi) * 1977-06-03 1978-12-04 Pharmaceutical Export Promotio Avmagningsmedel och foerfarande foer framstaellning daerav
US4210637A (en) * 1978-07-31 1980-07-01 Massachusetts Institute Of Technology Composition and method for suppressing appetite for calories as carbohydrates
US4897380A (en) * 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US5019594A (en) * 1989-11-28 1991-05-28 Interneuron Pharmaceuticals, Inc. Method for decreasing appetite
FR2657013B1 (fr) * 1990-01-18 1992-05-15 Medgenix Group Sa Composition dietetique a base de polypeptides et acides amines.

Also Published As

Publication number Publication date
IL127684A0 (en) 1999-10-28
EP0912181A1 (fr) 1999-05-06
KR20000023819A (ko) 2000-04-25
JP2000515139A (ja) 2000-11-14
WO1998002165A1 (fr) 1998-01-22
AU3666497A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
CA2260892A1 (fr) Coupe-faim
US5932624A (en) Vitamin supplement composition
US7115285B2 (en) Composition and method for appetite and craving suppression and mood enhancement
US7744930B2 (en) Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
US5730987A (en) Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
CA2616602A1 (fr) Methode de traitement ou de gestion du stress
US6265391B1 (en) Method for preventing peripheral nerve damage
US8323682B2 (en) Appetite suppressant product and method
US20040043442A1 (en) Use of betaine in functional products having blood pressure lowering effects
WO1999008681A1 (fr) Induction de neurotransmetteurs et d'activite neuropeptidique
US6017946A (en) Serotonin containing formulation for oral administration and method of use
JPH08503964A (ja) 食餌療法の低コレステロール血組成物
TWI413519B (zh) Bleaching acid or a pharmaceutically acceptable salt thereof as a prophylactic antihypertensive agent
CN109069532A (zh) 含铬组合物用于改善健康和健身
US20060094734A1 (en) Composition and method for inducing alertness
JP5602696B2 (ja) プロアントシアニジンによる性的機能及び性器血管系の改善
US20030113389A1 (en) Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels and for the prevention and treatment of cancer
WO1999034675A1 (fr) Procede favorisant la mobilisation et le catabolisme des lipides
CA2385774A1 (fr) Composes permettant de reduire la boulimie et de refrener l'appetit
MXPA99000660A (es) Supresion del apetito
JP4465963B2 (ja) 高脂血症の予防または改善用組成物
JPS6050165B2 (ja) 脳卒中の予防剤
WO1999024040A1 (fr) Stimulation de la production d'hormones
JP2005112832A (ja) 抗骨粗鬆症剤
MX2008001176A (es) Método para tratamiento o manejo del estrés

Legal Events

Date Code Title Description
FZDE Discontinued